Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Expert Insight
Spotlight Article

High dose systemic gene therapy: emerging trends on safety and efficacy

Trends and advances in gene therapy delivery and gene editing

Ying Kai Chan, Hansell H Stedman, Roland W Herzog, Guangping Gao & George M Church

Systemic delivery of adeno-associated viral (AAV) vectors has traditionally been used in the clinic for liver-directed programs such as hemophilia A and hemophilia B. With the approval of Zolgensma® for the treatment of spinal muscular atrophy type I (SMA1), high dose systemic gene therapy has become a promising approach for systemic and neuromuscular transduction for various indications. Here, we discuss emerging findings on safety and efficacy from recent clinical trials utilizing high dose systemic gene therapy. In particular, we highlight previously unappreciated observations related to safety, and discuss possible causes and future directions.

DOI: 10.18609/cgti.2020.066
Citation: Cell & Gene Therapy Insights 2020; 6(4), 569–575
Open access
This content is restricted to registered users. Click here to Register or Login here.
Twitter IconVisit Our Blog